SIRIO Pharma opens multimillion gummy production plant

18 Oct 2018

The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

Sirio Pharma has announced the opening of a gummy production plant at its new development and manufacturing facility in Ma’anshan (300 km West of Shanghai, China). This announcement comes 11 years after SIRIO opened its first gummy facility. The new site will be built in several phases and form a ‘Centre of Excellence’ covering an enormous 240,000 m2.

SIRIO Pharma opens multimillion gummy production plant

Phase Ⅰ of the site’s construction has just been completed and features a 26,000sqm gummy production plant and its associated building – designed to expedite development and manufacturing of gummy formulations for global customers.

“In the US and Europe in particular, there is a significant growth potential in gummy formulations – as they are seen as a more consumer-friendly dosage form. For many of the branded firms looking to enter this market early with customized formulations, we offer clear advantages. We can expedite development and even offer taste testing options during formulation. Alternatively, we also offer ready-to-go formulations for companies that are looking to enter the market quickly – because we have one of the largest ranges of existing gummy formulations of any global business. But as consumers become more discerning, we anticipate branded companies will increasingly need specialist gummy development partners and capabilities,” said Rui Yang, CSO of SIRIO Pharma.

The gummy production plant features integrated R&D and will increase production capacity to 2.4 billion gummies per year. SIRIO also expanded its ability to make innovative products such as liquid-filled, centre-filled, swirled and multicoloured gummies. In addition, SIRIO has hundreds of standard gummy formulation options suitable for market launch in the US and EU, and vegetarian options including carrageen and pectin, as well as sugar-free and low-sugar options.

“The advantage of running an integrated site is that we can develop a much more tailored product for customers, while also expediting development timelines, thanks to a large team of in-house gummy specialists - more than 10 scientists and formulation engineers dedicated to gummies. We anticipate exponential growth for the gummy lines in 2019. And obviously, with the new capacity we have, we can supply even for the largest of nutraceutical brands,” said Rui Yang, CSO of SIRIO Pharma.

Loren Israelsen, President, United Natural Products Alliance, on his recent visit to the new facility commented: “I have toured scores of dietary supplement factories around the world, but few equal Sirio's new gummy facility in terms of technology, state-of-the-art design and engineering, robotics, and R&D capabilities. This facility boasts world-class R&D and manufacturing and will help customers innovate new formulations for the fast-growing gummy market."

Read More

Related news

Clinical supply milestone reached for triple-negative breast cancer treatment

Clinical supply milestone reached for triple-negative breast cancer treatment

12 Jun 2019

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.

Read more 
Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

11 Jun 2019

No meaningful difference between the two study groups regardless of age, sex, race or ethnicity.

Read more 
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

6 Jun 2019

Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.

Read more 
Lilly gets its hands on non-opioid pain asset

Lilly gets its hands on non-opioid pain asset

4 Jun 2019

Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.

Read more 
Updated clinical trial simulation software saves time and money

Updated clinical trial simulation software saves time and money

3 Jun 2019

One customer saves $25m and 3 years' development time in their clinical development strategy.

Read more 
Merck bolsters oncology pipeline with acquisition

Merck bolsters oncology pipeline with acquisition

22 May 2019

Acquisition includes novel late-stage renal cell carcinoma candidate, PT2977.

Read more 
Follicum files patent application for new topical formulation for hair loss

Follicum files patent application for new topical formulation for hair loss

30 Apr 2019

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.

Read more 
Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more